Provided by Tiger Fintech (Singapore) Pte. Ltd.

Summit Hotel Properties

4.26
-0.1100-2.52%
Volume:575.26K
Turnover:2.46M
Market Cap:464.99M
PE:20.99
High:4.38
Open:4.37
Low:4.24
Close:4.37
Loading ...

BofA Upgrades Summit Hotel Properties to Neutral

MT Newswires Live
·
30 Apr

Summit Hotel Properties upgraded to Neutral from Underperform at BofA

TIPRANKS
·
30 Apr

INN or OHI: Which Is the Better Value Stock Right Now?

Zacks
·
29 Apr

Summit Hotel Properties Inc expected to post a loss of 2 cents a share - Earnings Preview

Reuters
·
29 Apr

Summit Hotel Properties Keeps Q1 Cash Dividend at $0.08 a Share, Payable May 30 to Holders May 16

MT Newswires Live
·
25 Apr

Press Release: SUMMIT HOTEL PROPERTIES DECLARES FIRST QUARTER 2025 DIVIDENDS

Dow Jones
·
25 Apr

Is the Options Market Predicting a Spike in Summit Hotel Properties Stock?

Zacks
·
23 Apr

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

GlobeNewswire
·
23 Apr

BofA Securities Adjusts Summit Hotel Properties Price Target to $5 From $7

MT Newswires Live
·
22 Apr

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

GlobeNewswire
·
16 Apr

Innocan Pharma Announces Closing of Private Placement

CNW Group
·
15 Apr

Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units

CNW Group
·
08 Apr

Remsense Technologies Teams Up With Investor-Focused News Platform; Shares Down 12%

MT Newswires Live
·
03 Apr

How Much Would It Take To Earn $100 A Month From Summit Hotel Properties Stock

Benzinga
·
03 Apr

BRIEF-Summit Hotel Properties Completes $275 Million Delayed Draw Term Loan Financing

Reuters
·
01 Apr

Summit Hotel Properties Completes $275 Million Delayed Draw Term Loan Financing

THOMSON REUTERS
·
01 Apr

Press Release: SUMMIT HOTEL PROPERTIES COMPLETES $275 MILLION DELAYED DRAW TERM LOAN FINANCING

Dow Jones
·
01 Apr

Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million

CNW Group
·
01 Apr

Press Release: Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Dow Jones
·
31 Mar

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
21 Mar